Stephen E.F. Spurgeon, M.D.
- Special Interest:
- Chronic Lymphocytic Leukemia
- Accepting Patients:
Dr. Spurgeon provides expertise in lymphoid malignancies. He often works with referring oncologists to develop treatment plans that can be effectively delivered in the community. He is also involved in a number of multicenter and investigator studies, including early phase studies for relapsed patients, especially in chronic lymphocytic leukemia. He collaborates with the OHSU Knight Cancer Institute's Center for Cell Signaling, evaluating signaling pathways and exploring the effects of new drugs on patient cancer samples, e.g., lymph nodes, bone marrow and peripheral blood. Dr. Spurgeon is a member of the multi-disciplinary lymphoid malignancies team that reviews each patient's ongoing management plan. All new and/or complicated lymphoid malignancy cases are reviewed by the multidisciplinary lymphoid malignancy tumor board. Dr. Spurgeon believes collaborations with colleagues within the OHSU Knight Cancer Institute, across the Northwest and around the country are essential, allowing patients access to unique therapeutic and research opportunities as well as to other experts in the field. Dr. Spurgeon participates regularly in medical school, patient, and physician education programs. He also sits on the OHSU Knight Cancer Institute scientific review committee.
M.D., Jefferson Medical College at Thomas Jefferson University, Philadelphia, PA, 2002
2002-2005. Residency: Oregon Health & Science University; Portland, Oregon 2005-2006. Chief Resident: Oregon Health & Science University; Portland, Oregon
2006-2009. Fellowship: Oregon Health & Science University; Portland, Oregon
American Board of Internal Medicine (Internal Medicine), 2005 American Board of Internal Medicine (Hematology), 2009 American Board of Internal Medicine (Medical Oncology), 2009